title: Impact of anti-drug antibodies in preclinical pharmacokinetic assessment.
abstract: The administration of human biotherapeutics is often associated with a higher incidence of immunogenicity in preclinical species. The presence of anti-drug antibodies (ADAs) in the test samples can affect the accurate measurement of therapeutic protein (TP) in bioanalytical methods designed to support pharmacokinetic (PK) and toxicokinetic (TK) assessments. The impact can vary depending on the bioanalytical method platform and study dosing design. The goal of this study is to evaluate the impact of ADA response on the bioanalytical methods in support of PK/TK and the associated study data interpretation. Sprague Dawley rats were administered with four weekly doses of 50 mg/kg TP, a humanized monoclonal antibody. The TP in serum samples was measured using three bioanalytical methods that quantified bound and/or unbound TP to ADA. The ADA response in the animals was classified into negative, low, medium, and high based on the magnitude of the response. The presence of ADA in samples led to discrepant TP measurements between the methods, especially at time points where the TP concentrations were low. This could be due to ADA interference to the accurate measurement of ADA-bound TP concentrations. The TP concentration at last time point (C last) was reduced by 82.8%, 98.6%, and 99.8%, respectively, for samples containing low, medium, and high levels of ADA. The interfering effects of the ADA on bioanalytical methods and exposure were evident as early as 2 weeks post-dosing. This modeling approach can provide the better understanding of ADA impact on PK exposure in multiple doses.
authors: Department of Pharmacokinetic and Drug Metabolism, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320, USA. tthway@amgen.com
authors: Theingi M
authors: TM
authors: Thway
authors: Ivan
authors: I
authors: Magana
authors: Ami
authors: A
authors: Bautista
authors: Vibha
authors: V
authors: Jawa
authors: Wen
authors: W
authors: Gu
authors: Mark
authors: M
authors: Ma
mesh_terms: D000818:Animals; D000906:Antibodies / Q000097:blood* / Q000276:immunology; D001685:Biological Factors / Q000097:blood* / Q000493:pharmacokinetics; D004353:Drug Evaluation, Preclinical / Q000379:methods; D006801:Humans; D051379:Mice; D004364:Pharmaceutical Preparations / Q000097:blood*; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000906:Antibodies; D001685:Biological Factors; D004364:Pharmaceutical Preparations
references: Bioanalysis. 2011 Aug;3(16):1799-803
references: 21877887
references: J Pharm Biomed Anal. 2012 Jan 25;58:65-70
references: 22005590
references: Bioanalysis. 2012 Oct;4(19):2357-65
references: 23088462
references: Fed Regist. 2012 May 18;77(97):29665-6
references: 22616137
references: AAPS J. 2012 Jun;14(2):296-302
references: 22407289
references: J Pharm Biomed Anal. 2009 Apr 5;49(3):613-8
references: 19150189
references: Curr Opin Microbiol. 2012 Jun;15(3):337-47
references: 22770538
references: Bioanalysis. 2011 Mar;3(5):487-98
references: 21388262
references: AAPS J. 2011 Mar;13(1):99-110
references: 21240643
references: AAPS J. 2007 May 25;9(2):E164-70
references: 17614358
references: AAPS J. 2012 Dec;14(4):843-9
references: 22941399